Keith Martin Giles from Roslyn, NY, age 67

Resumes

Keith Giles

View page

Work:

Norfolk Southern Corporation

Keith Giles

View page

Keith Giles

View page

Keith Giles

View page

Keith Giles East Orange, NJ

View page

Work:

Everyday Health Inc

2010 to Present
Benefits Manager
Everyday Health Inc
Washington, DC
2010 to Oct 2010
Senior Benefits Specialist
HEINEKEN USA INCORPORATED
White Plains, NY
2003 to Feb 2010
Human Resources Benefits Manager
HEINEKEN USA INCORPORATED
White Plains, NY
2000 to 2003
Human Resources Benefits Associate
HEINEKEN USA INCORPORATED
White Plains, NY
1997 to 2000
Human Resources Assistant

Education:

Manhattanville College
Purchase, NY
May 2009
M.S. in Organizational Development
Mercy College
Dobbs Ferry, NY
May 1996
B.S. in Business Administration

Business Records

Name / Title

Company / Classification

Phones & Addresses

Keith Giles
Manager

City of Cincinnati
Public Finance/Taxation/Monetary Policy · Executive Office · General Government · Legal Counsel/Prosecution · Legislative Body · Regulation/Administrative Transportation · Administrative General Economic Programs · Police Protection

(513) 352-3227, (513) 352-3221, (513) 352-3243, (513) 352-1923

Keith M. Giles
Director, Secretary

NAPLES CONDOMINIUM CORP. II

226 W Georgia St, Tallahassee, FL 32301
231 S Lasalle St, Chicago, IL

Keith M. Giles
Director, Secretary

MONACO DEVELOPMENT, INC

4401 Gulf Shr Blvd N, Naples, FL 33940
231 S Lasalle St, Chicago, IL

Publications

Us Patents

Method Of Improving Efficacy Of Melanoma Treatment

View page

US Patent:

20190353657, Nov 21, 2019

Filed:

May 15, 2019

Appl. No.:

16/413418

Inventors:

- New York NY, US
Keith Giles - New York NY, US

International Classification:

G01N 33/574
C07K 16/28
A61P 35/00
A61K 39/395
G01N 33/564

Abstract:

Provided are compositions and methods for determining whether or not an individual who has cancer is likely to develop immune-related adverse events (irAEs) because of treatment with an immune checkpoint inhibitor such as an anti-Programmed cell death protein 1 (anti-PD-1) checkpoint inhibitor, and/or anti-Cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) checkpoint inhibitor. Also provided are methods for treating an individual who has cancer with a checkpoint inhibitor and an agent to reduce the risk of toxicity from the checkpoint inhibitor, as well as administering agents to prevent or reduce the risk of toxicity during treatment.